|
1
|
Chao J, Zhao S and Sun H:
Dedifferentiation of hepatocellular carcinoma: molecular mechanisms
and therapeutic implications. Am J Transl Res. 12:2099–2109.
2020.PubMed/NCBI
|
|
2
|
Jiang H, Cao HJ, Ma N, Bao WD, Wang JJ,
Chen TW, Zhang EB, Yuan YM, Ni QZ, Zhang FK, et al: Chromatin
remodeling factor ARID2 suppresses hepatocellular carcinoma
metastasis via DNMT1-snail axis. Proc Natl Acad Sci USA.
117:4770–4780. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Rossi JZ and Finn
RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li L, Li L, Li W, Chen T, Zou B, Zhao L,
Wang H, Wang X, Xu L, Liu X, et al: TAp73-induced
phosphofructokinase-1 transcription promotes the warburg effect and
enhances cell proliferation. Nat Commun. 9:46832018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hensley CT, Wasti AT and DeBerardinis RJ:
Glutamine and cancer: Cell biology, physiology, and clinical
opportunities. J Clin Invest. 123:3678–3684. 2013. View Article : Google Scholar
|
|
6
|
Carracedo A, Cantley LC and Pandolfi PP:
Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev
Cancer. 13:227–232. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li L and Wang H: Heterogeneity of liver
cancer and personalized therapy. Cancer Lett. 379:191–197. 2016.
View Article : Google Scholar
|
|
8
|
Center MM and Jemal A: International
trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers
Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marengo A, Rosso C and Bugianesi E: Liver
Cancer: Connections with obesity, fatty liver, and cirrhosis. Annu
Rev Med. 67:103–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu N and Dahlback B: A novel human
apolipoprotein (apoM). J Biol Chem. 274:31286–31290. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurano M, Tsukamoto K, Shimizu T, Kassai
H, Nakao K, Aiba A, Hara M and Yatomi Y: Protection against insulin
resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes.
69:867–881. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurano M and Yatomi Y: Sphingosine
1-phosphate and atherosclerosis. J Atheroscler Thromb. 25:16–26.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Lam SM, Liu H, Luo G, Zhang J, Yao
S, Li J, Zheng L, Xu N, Zhang X and Shui G: Comprehensive
lipidomics in apoM(−/-) mice reveals an overall state of metabolic
distress and attenuated hepatic lipid secretion into the
circulation. J Genet Genomics. 47:523–534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang J, Wu C, Luo G, Zheng L, Chen L,
Zhang X and Xu N: Expression of apolipoprotein M in human
hepatocellular carcinoma tissues. Acta Histochem. 113:53–57. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu YW, Chen ZP, Hu XM, Zhao JY, Huang JL,
Ma X, Li SF, Qiu YR, Wu XJ, Sha YH, et al: The
miR-573/apoM/Bcl2A1-dependent signal transduction pathway is
essential for hepatocyte apoptosis and hepatocarcinogenesis.
Apoptosis. 20:1321–1337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu M, Pan L, Sang C, Mu Q, Zheng L, Luo G
and Xu N: Apolipoprotein M could inhibit growth and metastasis of
SMMC7721 cells via vitamin D receptor signaling. Cancer Manag Res.
11:3691–3701. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai Y, Pei W, Zhang X, Zheng H, Hua C, Min
J, Hu L, Du S, Gong Z, Gao J and Zhang Y: ApoM is an important
potential protective factor in the pathogenesis of primary liver
cancer. J Cancer. 12:4661–4671. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Zhang P, Gao J and Huang Q:
Autophagy dysregulation caused by ApoM deficiency plays an
important role in liver lipid metabolic disorder. Biochem Biophys
Res Commun. 495:2643–2648. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimano H and Sato R: SREBP-regulated
lipid metabolism: Convergent physiology-divergent pathophysiology.
Nat Rev Endocrinol. 13:710–730. 2017. View Article : Google Scholar
|
|
20
|
Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL
and Song BL: Inhibition of SREBP by a small molecule, betulin,
improves hyperlipidemia and insulin resistance and reduces
atherosclerotic plaques. Cell Metab. 13:44–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng C, Geng F, Cheng X and Guo D: Lipid
metabolism reprogramming and its potential targets in cancer.
Cancer Commun (Lond). 38:272018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin F, Feng F, Wang L, Wang X, Li Z and
Cao Y: SREBP-1 inhibitor betulin enhances the antitumor effect of
Sorafenib on hepatocellular carcinoma via restricting cellular
glycolytic activity. Cell Death Dis. 10:6722019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
An L, Zeng HM, Zheng RS, Zhang SW, Sun KX,
Zou XN, Chen R, Wang SM, Gu XY, Wei WW and He J: Liver cancer
epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:721–727.
2019.(In Chinese).
|
|
24
|
Borup A, Christensen PM, Nielsen LB and
Christoffersen C: Apolipoprotein M in lipid metabolism and
cardiometabolic diseases. Curr Opin Lipidol. 26:48–55. 2015.
View Article : Google Scholar
|
|
25
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schoneberg T, Kloos M, Brüser A,
Kirchberger J and Sträter N: Structure and allosteric regulation of
eukaryotic 6-phosphofructokinases. Biol Chem. 394:977–993. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dorotea D, Koya D and Ha H: Recent
insights Into SREBP as a direct mediator of kidney fibrosis via
lipid-independent pathways. Front Pharmacol. 11:2652020. View Article : Google Scholar
|
|
28
|
Xu C, Zhang L, Wang D, Jiang S, Cao D,
Zhao Z, Huang M and Jin J: Lipidomics reveals that sustained
SREBP-1-dependent lipogenesis is a key mediator of
gefitinib-acquired resistance in EGFR-mutant lung cancer. Cell
Death Discov. 7:3532021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tao T, Su Q, Xu S, Deng J, Zhou S, Zhuang
Y, Huang Y, He C, He S, Peng M, et al: Down-regulation of PKM2
decreases FASN expression in bladder cancer cells through
AKT/mTOR/SREBP-1c axis. J Cell Physiol. 234:3088–3104. 2019.
View Article : Google Scholar
|
|
30
|
Horton JD, Goldstein JL and Brown MS:
SREBPs: Activators of the complete program of cholesterol and fatty
acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002.
View Article : Google Scholar
|
|
31
|
Yi J, Zhu J, Wu J, Thompson CB and Jiang
X: Oncogenic activation of PI3K-AKT-mTOR signaling suppresses
ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA.
117:31189–31197. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng Z, Zeng Y, Zhu X, Tan Y, Li Y, Li Q
and Yi G: ApoM-S1P modulates Ox-LDL-induced inflammation through
the PI3K/Akt signaling pathway in HUVECs. Inflammation. 42:606–617.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Tang X and Li S: Propofol promotes
migration, alleviates inflammation, and apoptosis of
lipopolysaccharide-induced human pulmonary microvascular
endothelial cells by activating PI3K/AKT signaling pathway via
upregulating APOM expression. Drug Dev Res. 83:397–406. 2021.
View Article : Google Scholar : PubMed/NCBI
|
